Anti-proliferative and anti-invasive properties of a purified fraction from Streptomyces sp. H7372

International Journal of Oncology

Volumn 37, Issue 5, 2010, Pages 1229-1241

  Yip, Wai Kien ^a   Cheenpracha, Sarot ^b   Chang, Leng Chee ^b   Ho, Coy Choke ^c   Seow, Heng Fong ^a  

^a Malaysia   (Malaysia)

^b UNIVERSITY OF HAWAII AT HILO   (United States)

^c UNIVERSITI MALAYSIA SABAH   (Malaysia)

Author keywords

Breast cancer; Cell cycle; Cytostasis; Invasion; Proteolytic activity; Streptomyces

Indexed keywords

COLLAGEN TYPE 4; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLINE; RETINOBLASTOMA PROTEIN;

ACTINOBACTERIA; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CYTOSTASIS; CYTOTOXICITY; ENZYME DEGRADATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; STREPTOMYCES; WESTERN BLOTTING;

EID: 77957874278     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000774     Document Type: Article

References (54)

1. Grenon NN and Chan J: Managing toxicities associated with colorectal cancer chemotherapy and targeted therapy: a new guide for nurses. Clin J Oncol Nurs 13: 285-296, 2009.
2. Berdy J: Bioactive microbial metabolites. J Antibiot (Tokyo) 58: 1-26, 2005.
3. Olano C, Mendez C and Salas JA: Antitumor compounds from marine actinomycetes. Mar Drugs 7: 210-248, 2009.
4. Newman DJ and Cragg GM: Natural products as sources of new drugs over the last 25 years. J Nat Prod 70: 461-477, 2007.
5. Olano C, Mendez C and Salas JA: Antitumor compounds from actinomycetes: from gene clusters to new derivatives by combinatorial biosynthesis. Nat Prod Rep 26: 628-660, 2009.
6. Cheah HY: Isolation of actinomycetes from mangroves in Sabah and screening for inhibitors against eukaryotic signal transduction. Universiti Malaysia Sabah, 2003.
7. Voo CLY, Lai NS, Kibat C, et al: Actinomycetes and fungi isolated from Maliau Basin, Sabah and the screening for novel secondary metabolites against eukaryotic signal transduction and mycobacterium. J Trop Biol Conserv 3: 11-56, 2007.
8. Bellacosa A, Kumar CC, Di Cristofano A and Testa JR: Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 94: 29-86, 2005. (Pubitemid 41202364)
9. Dhillon AS, Hagan S, Rath O and Kolch W: MAP kinase signalling pathways in cancer. Oncogene 26: 3279-3290, 2007. (Pubitemid 46763021)
10. Borley AC, Hiscox S, Gee J, et al: Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells. Breast Cancer Res 10: R103, 2008.
11. Koblinski JE, Kaplan-Singer BR, van Osdol SJ, et al: Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis. Cancer Res 65: 7370-7377, 2005.
12. Liotta LA: Tumor invasion and metastases: role of the basement membrane. Warner-Lambert Parke-Davis Award lecture. Am J Pathol 117: 339-348, 1984.
13. Ree AH, Bjornland K, Brunner N, et al: Regulation of tissue-degrading factors and in vitro invasiveness in progression of breast cancer cells. Clin Exp Metastasis 16: 205-215, 1998.
14. Zhen MC, Huang XH, Wang Q, et al: Green tea polyphenol epigallocatechin-3-gallate suppresses rat hepatic stellate cell invasion by inhibition of MMP-2 expression and its activation. Acta Pharmacol Sin 27: 1600-1607, 2006.
15. Kato-Stankiewicz J, Hakimi I, Zhi G, et al: Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proc Natl Acad Sci USA 99: 14398-14403, 2002.
16. Kleinman HK, McGarvey ML, Hassell JR, et al: Basement membrane complexes with biological activity. Biochemistry 25: 312-318, 1986.
17. Liotta LA, Thorgeirsson UP and Garbisa S: Role of collagenases in tumor cell invasion. Cancer Metastasis Rev 1: 277-288, 1982.
18. Melchiori A, Albini A, Ray JM and Stetler-Stevenson WG: Inhibition of tumor cell invasion by a highly conserved peptide sequence from the matrix metalloproteinase enzyme prosegment. Cancer Res 52: 2353-2356, 1992.
19. Sameni M, Moin K and Sloane BF: Imaging proteolysis by living human breast cancer cells. Neoplasia 2: 496-504, 2000. (Pubitemid 32098684)
20. Botos J, Smith R III and Kochevar DT: Retinoblastoma function is a better indicator of cellular phenotype in cultured breast adenocarcinoma cells than retinoblastoma expression. Exp Biol Med 227: 354-362, 2002.
21. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323-330, 1995.
22. Chellappan SP, Hiebert S, Mudryj M, Horowitz JM and Nevins JR: The E2F transcription factor is a cellular target for the RB protein. Cell 65: 1053-1061, 1991. (Pubitemid 121001693)
23. Xiao ZX, Chen J, Levine AJ, et al: Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375: 694-698, 1995.
24. Welch PJ and Wang JY: A C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle. Cell 75: 779-790, 1993.
25. Knudsen ES and Wang JY: Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J Biol Chem 271: 8313-8320, 1996.
26. Knudsen ES and Wang JY: Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol Cell Biol 17: 5771-5783, 1997.
27. Dyson N: The regulation of E2F by pRB-family proteins. Genes Dev 12: 2245-2262, 1998.
28. Connell-Crowley L, Harper JW and Goodrich DW: Cyclin D1/ Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell 8: 287-301, 1997. (Pubitemid 27097944)
29. Rubin SM, Gall AL, Zheng N and Pavletich NP: Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism for phosphorylation-induced E2F release. Cell 123: 1093-1106, 2005. (Pubitemid 41785423)
30. Adams PD: Regulation of the retinoblastoma tumor suppressor protein by cyclin/cdks. Biochim Biophys Acta 1471: M123-M133, 2001. (Pubitemid 32206688)
31. Paternot S, Arsenijevic T, Coulonval K, Bockstaele L, Dumont JE and Roger PP: Distinct specificities of pRb phosphorylation by CDK4 activated by cyclin D1 or cyclin D3: differential involvement in the distinct mitogenic modes of thyroid epithelial cells. Cell Cycle 5: 61-70, 2006.
32. Zarkowska T and Mittnacht S: Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases. J Biol Chem 272: 12738-12746, 1997. (Pubitemid 27203373)
33. Driscoll B, T'Ang A, Hu YH, et al: Discovery of a regulatory motif that controls the exposure of specific upstream cyclin-dependent kinase sites that determine both conformation and growth suppressing activity of pRb. J Biol Chem 274: 9463-9471, 1999.
34. Pan W, Sun T, Hoess R and Grafstrom R: Defining the minimal portion of the retinoblastoma protein that serves as an efficient substrate for cdk4 kinase/cyclin D1 complex. Carcinogenesis 19: 765-769, 1998. (Pubitemid 28376765)
35. Takaki T, Fukasawa K, Suzuki-Takahashi I, et al: Preferences for phosphorylation sites in the retinoblastoma protein of D-type cyclin-dependent kinases, Cdk4 and Cdk6, in vitro. J Biochem 137: 381-386, 2005. (Pubitemid 40628445)
36. Harbour JW, Luo RX, Dei Santi A, Postigo AA and Dean DC: Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 98: 859-869, 1999. (Pubitemid 29446902)
37. Lundberg AS and Weinberg RA: Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 18: 753-761, 1998.
38. Ezhevsky SA, Ho A, Becker-Hapak M, Davis PK and Dowdy SF: Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo. Mol Cell Biol 21: 4773-4784, 2001. (Pubitemid 32588257)
39. Moldovan GL, Pfander B and Jentsch S: PCNA, the maestro of the replication fork. Cell 129: 665-679, 2007.
40. Maga G and Hubscher U: Proliferating cell nuclear antigen (PCNA): a dancer with many partners. J Cell Sci 116: 3051-3060, 2003. (Pubitemid 37038954)
41. Mueller PR, Coleman TR, Kumagai A and Dunphy WG: Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. Science 270: 86-90, 1995.
42. Parker LL and Piwnica-Worms H: Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science 257: 1955-1957, 1992.
43. Potapova TA, Daum JR, Byrd KS and Gorbsky GJ: Fine tuning the cell cycle: activation of the Cdk1 inhibitory phosphorylation pathway during mitotic exit. Mol Biol Cell 20: 1737-1748, 2009.
44. O'Farrell PH: Triggering the all-or-nothing switch into mitosis. Trends Cell Biol 11: 512-519, 2001.
45. Miyachi T, Adachi M, Hinoda Y and Imai K: Butyrate augments interferon-alpha-induced S phase accumulation and persistent tyrosine phosphorylation of cdc2 in K562 cells. Br J Cancer 79: 1018-1024, 1999. (Pubitemid 29087869)
46. Tyagi A, Singh RP, Agarwal C, Siriwardana S, Sclafani RA and Agarwal R: Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Carcinogenesis 26: 1978-1987, 2005.
47. Barsky SH, Siegal GP, Jannotta F and Liotta LA: Loss of basement membrane components by invasive tumors but not by their benign counterparts. Lab Invest 49: 140-147, 1983. (Pubitemid 13039938)
48. Havenith MG, Arends JW, Simon R, Volovics A, Wiggers T and Bosman FT: Type IV collagen immunoreactivity in colorectal cancer. Prognostic value of basement membrane deposition. Cancer 62: 2207-2211, 1988.
49. Overall CM and Kleifeld O: Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6: 227-239, 2006.
50. Vizoso FJ, Gonzalez LO, Corte MD, et al: Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer 96: 903-911, 2007.
51. Kalluri R: Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 3: 422-433, 2003.
52. Jones JL and Walker RA: Control of matrix metalloproteinase activity in cancer. J Pathol 183: 377-379, 1997.
53. Zeng ZS, Cohen AM and Guillem JG: Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis 20: 749-755, 1999.
54. Vasse M, Thibout D, Paysant J, Legrand E, Soria C and Crepin M: Decrease of breast cancer cell invasiveness by sodium phenylacetate (NaPa) is associated with an increased expression of adhesive molecules. Br J Cancer 84: 802-807, 2001.